Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47
Cancer Communications · 2025
DOI: 10.1002/cac2.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, 2025. Verfasst von Jie Zhang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, CD47 Antigen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Zhejiang Province, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Background
Only a few bladder cancer patients benefit from anti‐programmed cell death protein 1/programmed cell death ligand 1 immunotherapy. The cluster of differentiation 47 (CD47) plays an important role in tumor immune evasion. CD47 is a highly glycosylated protein, however, the mechanisms governing CD47 glycosylation and its potential role in immunosuppression are unclear. Therefore, this study aimed to evaluate the function of CD47 glycosylation in bladder cancer.
Methods
Western blotting, immunohistochemistry, and flow cytometry were used to measure protein expression, protein‐protein interactions, and phagocytosis in bladder cancer. A murine model was employed to investigate the impact of mannosidase alpha class 1B member 1 (MAN1B1) modification of CD47 on anti‐phagocytosis in vivo. An ex vivo model, patient‐derived tumor‐like cell clusters, was used to examine the effect of targeting MAN1B1 on phagocytosis.
Results
Our research identified that aberrant CD47 glycosylation was responsible for its immunosuppression. The glycosyltransferase MAN1B1 responsible for CD47 glycosylation was highly expressed in bladder cancer. Abnormal activation of extracellular signal‐regulated kinase (ERK) was significantly associated with MAN1B1 stability by regulating the interaction between MAN1B1 and the E3 ubiquitin ligase HMG‐CoA reductase degradation 1 (HRD1). Mechanistically, abnormally activated ERK stabilized MAN1B1, resulting in the glycosylation of CD47 and facilitating immune evasion by enhancing its interaction with signal‐regulatory protein alpha (SIRP‐α). In vitro and in vivo experiments demonstrated that MAN1B1 knockout weakened CD47‐mediated anti‐phagocytosis. MAN1B1 inhibitors promoted phagocytosis without causing anemia, offering a safe alternative to anti‐CD47 therapy.
Conclusions
This comprehensive analysis uncovered that ERK activation stabilizes MAN1B1 by regulating the interaction between MAN1B1 and HRD1, facilitates immune evasion via CD47 glycosylation, and presents new potential targets and strategies for cancer immunotherapy that do not cause anemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
- College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, P. R. China.
- Hangzhou HuaAn Biotechnology Co., Ltd, Hangzhou, Zhejiang, P. R. China.
- Hangzhou Enyor Biotechnology Co., Ltd, Hangzhou, Zhejiang, P. R. China.
- Hangzhou Viji Biotechnology Co., Ltd, Hangzhou, Zhejiang, P. R. China.
- National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
ORCID-Profile: Jie Zhang, Chen Zhang, Ruichen Zang, Weiwu Chen, Yining Guo, Jing Le, Kunyu Wang, Haobo Fan, Xudong Wang, Sisi Mo, Peng Gao, Wenhao Guo, Xinrong Jiang, Fengbin Gao, Yicheng Chen, Yanlan Yu, Guoqing Ding
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhang, J., Zhang, C., Zang, R., Chen, W., Guo, Y., Jiang, H., Le, J., Wang, K., Fan, H., Wang, X., Mo, S., Gao, P., Guo, W., Jiang, X., Gao, F., Jiang, J., Zheng, J., Chen, Y., Chen, Y., …, & Ding, G. (2025). Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47. Cancer Communications. https://doi.org/10.1002/cac2.70040
Vancouver
Zhang J, Zhang C, Zang R, Chen W, Guo Y, Jiang H, et al. Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47. Cancer Communications. 2025. doi:10.1002/cac2.70040
BibTeX
@article{Zhang2025,
author = {Zhang, Jie and Zhang, Chen and Zang, Ruichen and Chen, Weiwu and Guo, Yining and Jiang, Haofei and Le, Jing and Wang, Kunyu and Fan, Haobo and Wang, Xudong and Mo, Sisi and Gao, Peng and Guo, Wenhao and Jiang, Xinrong and Gao, Fengbin and Jiang, Junming and Zheng, Juyan and Chen, Yuxing and Chen, Yicheng and Yu, Yanlan and Ding, Guoqing},
title = {Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47},
journal = {Cancer Communications},
year = {2025},
doi = {10.1002/cac2.70040}
}
EUVIMED